賽諾醫療(688108.SH):NOVA顱內藥物洗脱支架臨牀研究成果發表
格隆匯1月5日丨賽諾醫療(688108.SH)公佈,近日,公司收到承接“評價NOVA顱內藥物洗脱支架系統臨牀使用的安全性和有效性的前瞻性、多中心、隨機對照研究”的組長單位首都醫科大學附屬北京天壇醫院通知,由首都醫科大學附屬北京天壇醫院繆中榮教授牽頭,聯合全國15家在神經介入領域具有影響力且手術經驗豐富的醫院共同完成的“評價NOVA顱內藥物洗脱支架系統臨牀使用的安全性和有效性的前瞻性、多中心、隨機對照研究”臨牀研究成果於2022年1月4日在國際頂級醫學期刊《JAMA Neurology》(美國醫學會雜誌——神經學分卷)發表(JAMA與新英格蘭醫學雜誌(NEJM)、柳葉刀(Lancet)和英國醫學期刊(BMJ)並稱為“四大頂級醫學期刊”。JAMA Neurology是JAMA的家族成員,在國際神經學領域具有極為重要的影響力。)
研究結果顯示:在有效性上,NOVA顱內藥物洗脱支架植入一年內的支架內再狹窄發生率顯著低於金屬裸支架組(9.5%vs30.2%,p<0.01),兩組具有統計學差異(藥物支架組可以比金屬裸支架組降低再狹窄發生率68.5%);NOVA顱內藥物洗脱支架組植入後31天至1年內缺血性腦卒中發生率也低於金屬裸支架組(0.8%vs6.9%,p=0.03),兩組具有統計學差異(較金屬裸支架組,NOVA藥物支架組降低1年內腦卒中再發生率88.4%)。在安全性上,30天內任何腦卒中或死亡兩組沒有統計學差異。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.